The effects of synbiotic supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes: a randomised, double-blind, placebo-controlled trial.
To the best of our knowledge, data on the effects of synbiotic supplementation on markers of insulin metabolism and lipid concentrations in patients with gestational diabetes mellitus (GDM) are scarce. The aim of the current study was to determine the effects of synbiotic supplementation on markers of insulin metabolism and lipid profiles in GDM patients. In total, seventy patients with GDM aged 18-40 years were assigned to two groups - the synbiotic group (n 35) and the placebo group (n 35) - in this randomised, double-blind, placebo-controlled trial. Patients in the synbiotic group received a daily capsule that contained three viable and freeze-dried strains: Lactobacillus acidophilus, Lactobacillus casei and Bifidobacterium bifidum (2×109 colony-forming units/g each) plus 800 mg inulin for 6 weeks. Fasting blood samples were collected at the beginning and week 6 to quantify related markers. After 6 weeks of intervention, compared with the placebo, synbiotic supplementation led to a significant decrease in serum insulin levels (-1·5 (sd 5·9) v. +4·8 (sd 11·5) µIU/ml, P=0·005), homoeostatic model assessment for insulin resistance (-0·4 (sd 1·3) v. +1·1 (sd 2·7), P=0·003) and homoeostatic model assessment for β cell function (-5·1 (sd 24·2) v. +18·9 (sd 45·6), P=0·008) and a significant increase in quantitative insulin sensitivity check index (+0·01 (sd 0·01) v. -0·007 (sd 0·02), P=0·02). In addition, synbiotic intake significantly decreased serum TAG (-14·8 (sd 56·5) v. +30·4 (sd 37·8) mg/dl, P<0·001) and VLDL-cholesterol concentrations (-3·0 (sd 11·3) v. +6·1 (sd 7·6) mg/dl, P<0·001) compared with the placebo. Overall, the results of this study demonstrate that taking synbiotic supplements for 6 weeks among patients with GDM had beneficial effects on markers of insulin metabolism, TAG and VLDL-cholesterol concentrations.
1Department of Gynecology and Obstetrics,School of Medicine,Iran University of Medical Sciences,PO Box 83121625, Tehran,Iran.
Shahnaz
S
Ahmadi
3Department of Gynecology and Obstetrics,School of Medicine,Endocrinology and Metabolism Research Center,Arak University of Medical Sciences,PO Box 6618634683, Arak,Iran.
Mehri
M
Jamilian
4Science Department, Science Faculty,Islamic Azad University,Tehran Central Branch,PO Box 83121625, Tehran,Iran.
Maryam
M
Tajabadi-Ebrahimi
5Department of Microbiology, Science Faculty,Islamic Azad University,Arak Branch,PO Box 6618634683, Arak,Iran.
Parvaneh
P
Jafari
6Research Center for Biochemistry and Nutrition in Metabolic Diseases,Kashan University of Medical Sciences,PO Box 8715988141, Kashan,Iran.
Zatollah
Z
Asemi
D000293:Adolescent; D000328:Adult; D000069985:Bifidobacterium bifidum / Q000254:growth & development; D015415:Biomarkers / Q000097:blood; D016640:Diabetes, Gestational / Q000178:diet therapy* / Q000378:metabolism / Q000382:microbiology / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology / Q000517:prevention & control*; D007333:Insulin Resistance; D057194:Intention to Treat Analysis; D007444:Inulin / Q000627:therapeutic use; D007492:Iran; D007779:Lactobacillus acidophilus / Q000254:growth & development; D007780:Lacticaseibacillus casei / Q000254:growth & development; D008055:Lipids / Q000097:blood; D059012:Lost to Follow-Up; D010352:Patient Dropouts; D011247:Pregnancy; D039401:Prenatal Nutritional Physiological Phenomena; D058616:Synbiotics; D055815:Young Adult
D015415:Biomarkers; D008055:Lipids; D007444:Inulin
 CFU colony-forming units;  FOS fructo-oligosaccharides;  FPG fasting plasma glucose;  GDM gestational diabetes mellitus;  HOMA-IR homoeostasis model of assessment for insulin resistance; Gestational diabetes mellitus; Insulin resistance; Lipid profiles; Synbiotic supplementation